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34 Non-alcoholic fatty liver (NAFLD) disease is now a major public health concern with an estimated 
35 prevalence of 25-30% of adults in many countries. Strongly associated with obesity and the metabolic 
36 syndrome, the pathogenesis of NAFLD is dependent on complex interactions between genetic and 
37 environmental factors that are not completely understood. Weight loss through diet and lifestyle 
38 modification underpins clinical management; however, the roles of individual dietary nutrients (e.g. 
39 saturated and omega-3 fatty acids; fructose, vitamin D, vitamin E) in the pathogenesis or treatment 
40 of NAFLD are only partially understood. Systems biology offers valuable interdisciplinary methods 
41 that are arguably ideal for application to the studying of chronic diseases such as NAFLD, and the 
42 roles of nutrition and diet in their molecular pathogenesis. Although current in silico models are 
43 incomplete, computational tools are rapidly evolving and human metabolism can now be simulated 
44 at the genome scale. This article will review NAFLD and its pathogenesis, including the roles of 
45 genetics and nutrition in the development and progression of disease. In addition, the article 
46 introduces the concept of systems biology and reviews recent work utilising genome-scale metabolic 
47 networks (GSMNs) and developing multi-scale models of liver metabolism relevant to NAFLD. A 
48 future is envisioned where individual genetic, proteomic and metabolomic information can be 
49 integrated computationally with clinical data, yielding mechanistic insight into the pathogenesis of 
50 chronic diseases such as NAFLD, and informing personalized nutrition and stratified medicine 
51 approaches for improving prognosis.
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52 Non-alcoholic fatty liver disease
53 Introduction
54 Non-alcoholic fatty liver (NAFLD) is defined by fat accumulation in the liver in the absence of excess 
55 alcohol consumption. Described histologically, NAFLD may range from simple steatosis (non-
56 alcoholic fatty liver; NAFL), where there is fatty infiltration but no evidence of hepatocellular injury, 
57 to non-alcoholic steatohepatitis (NASH), where there is evidence of inflammation and ballooning, 
58 with or without fibrosis(1). Although the early stage of NAFL is often considered benign, 25% of 
59 patients will progress to more serious disease(2,3). NAFLD is now the second most common cause of 
60 chronic liver disease among individuals listed for liver transplantation in the United States(4), and in 
61 the United Kingdom (UK) and Europe, the number of NAFLD-related liver transplantation has 
62 increased dramatically within the last ten years(5). Significantly, there are currently no licensed 
63 pharmaceutical agents specific for the treatment of NAFLD; although several agents, including 
64 dietary supplements, are in Phase 2 and Phase 3 clinical trials(6). Given the close association between 
65 NAFLD and obesity, weight loss through dietary and lifestyle intervention is the mainstay of current 
66 clinical management(1,7,8). 
67 Diagnosis
68 Currently available diagnostic tools (liver enzymes, imaging and biopsy) are either non-specific, 
69 expensive, or invasive. The lack of an acceptable, inexpensive diagnostic tool makes large-scale 
70 population studies difficult(9). Elevated liver enzymes (aspartate and alanine transaminases) are often 
71 used to define suspected NAFLD at a population level. However, the majority (79%) of individuals 
72 diagnosed with NAFLD by MRI in a large population study had normal transaminase levels(10), so 
73 relying on this measure significantly underestimates the burden of disease. Imaging is non-invasive 
74 but, in the case of MRI or magnetic resonance elastography, it can be expensive and not accessible 
75 to all. Alternatively, in the case of ultrasound and transient elastography (fibroscan), it can be 
76 somewhat insensitive for the staging of NASH and fibrosis. While liver biopsies are the gold standard 
77 for staging of NASH and fibrosis, required for licencing purposes in pharmacological trials(11), 
78 biopsies have their limitations, including issues with inter-rater reliability, sampling error, cost, and 
79 acceptability for monitoring the condition in the long term. 
80 NAFLD is closely associated with obesity and metabolic disorders. In a large meta-analysis 
81 of 86 studies, with a sample size of more than 8.5 million persons from 22 countries, more than 80% 
82 of individuals with NASH and 51% of individuals with NAFL were obese. Type 2 diabetes co-
83 occurred in 47% of NASH cases and 23% of NAFL cases; metabolic syndrome was found in 71% 
84 NASH patients and 41% of NAFL patients(12). For these reasons, clinical guidelines for NAFLD 
85 diagnosis(1,7,8) do not advocate general population screening, but stress that NAFLD is to be suspected 
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86 in individuals with type 2 diabetes or the metabolic syndrome; defined as 3 or more of 5 risk factors 
87 for cardiovascular disease and type 2 diabetes: hypertension, hypertriacylglycerolaemia, lowered 
88 high-density lipoprotein cholesterol, raised fasting glucose, and central obesity defined by increased 
89 waist circumference(13).
90 Prevalence
91 Given the challenges of NAFLD diagnosis, the prevalence of NAFLD can only be estimated and 
92 estimates vary depending on the diagnostic tool used. Nonetheless, it is clear that the prevalence of 
93 NAFLD varies by region and ethnicity, and the global prevalence of NAFLD is estimated to be 
94 24%(14).  The highest reported rates are in the Middle East (32%) and South America (31%), followed 
95 by Asia (27%), the US and the UK (24 and 23%)(14). Recent reviews of the epidemiology of NAFLD 
96 have highlighted surprising high prevalence in Asia (27% pooled estimate(12)), with country-specific 
97 estimates ranging from 15-40% for China, 25-30% for Japan, and 27-30% for Korea and India(15). 
98 Prevalence estimates in North America have ranged from 11-46% dependent on diagnostic modality 
99 and population studied; a recent meta-analysis with random effects model concluded a pooled average 
100 of 24% [19, 29%] by ultrasound but only 13% by blood testing(12). Prevalence in the US also depends 
101 on ethnicity with Hispanic Americans at highest risk (53%) relative to Caucasians (44%) and African 
102 Americans (35%)(10); while American Indians have a prevalence as low as 13%(16). Genetic 
103 variability, discussed in detail later, likely explains some, but not all of the differences in risk. The 
104 heritability of liver fat and fibrosis has estimated to be 39-52% and 50% respectively(17,18), 
105 underscoring that the environment also plays a large role in NAFLD development. Estimates of global 
106 NASH prevalence range from 1.5-6.5%(14), with estimates of 6% and 2% prevalence for NASH and 
107 NASH-related cirrhosis in the United States(2). In sum, NAFLD is a common chronic liver disease 
108 worldwide.
109 Natural history
110 As with prevalence, defining the natural history of disease progression in NAFLD has been hampered 
111 by the reliance on liver biopsies. While only recently the disease was perceived as progressing 
112 somewhat linearly from NAFL to NASH, then to NASH plus fibrosis, and then to cirrhosis, and end 
113 stage liver disease requiring transplantation, including occasionally hepatocellular carcinoma 
114 (HCC)(19); this perspective continues to evolve as outlined (Fig. 1). While simple steatosis in the 
115 absence of fibrosis is generally thought to have a more benign course of disease in terms of liver-
116 specific outcomes and mortality(20,21), some patients with NAFL, so-called rapid progressors can 
117 progress towards well-defined NASH with bridging fibrosis within a very few years(22). In addition, 
118 as diagrammed (Fig. 1), based on current data it can-not be excluded that in some cases, perhaps 
119 dependent on genetic susceptibilities, a NASH liver may arise from a normal liver(23). Moreover, an 
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120 increasing number of studies suggests that HCC can develop in a non-cirrhotic liver, further altering 
121 the early linear model of NAFLD natural history (Fig. 1)(24-26). Increased risk for HCC in NASH 
122 likely relates to body weight, as 80% of patients with NASH are also obese(12). A recent population-
123 based cohort study of 5.24 million UK adults has demonstrated large increases in risk (HR >1·1 per 
124 5 kg/m²) for liver cancer occurring in a linear fashion with increasing BMI(27). 
125 Progression to severe liver disease in adults is in the order of decades(2,12,28). Multiple large 
126 retrospective cohort studies (>600 patients, mean follow-up 20 years) have now demonstrated that it 
127 is fibrosis, rather than NASH, on index biopsy that is associated most strongly with increased risk of 
128 mortality and liver-related outcomes such as decompensation or transplant(21,29). This work suggests 
129 NAFLD activity score is not clearly prognostic(29), and time to development of severe liver disease is 
130 dependent on fibrosis stage at presentation. Approximately 2226 years for F0-1, 9.3 years for F2, 
131 2.3 years for F3, and 0.9 years to liver decompensation in F4 fibrosis(21). However, the risk of 
132 selection bias for follow-up liver biopsy in single-centre studies is substantial, and rates of 
133 progression may thus be overestimated in the general population. Some have expressed concern about 
134 the risk of over diagnosis in screening and monitoring individuals for NAFLD, when the majority 
135 will not develop advanced liver disease(30). 
136 Conversely, a recent population study (n=3,041 adults >45) assessed fibrosis by transient 
137 elastography and demonstrated clinically relevant fibrosis in the community was a concerning 
138 5.6%(31). Furthermore, modelling indicates the burden of NASH, end-stage liver disease 
139 (decompensated cirrhosis, HCC), and liver-related deaths will continue to grow(32).  Importantly, 
140 while severe liver outcomes may be the third rather than the primary cause of death in NASH patients, 
141 worryingly the primary and secondary causes of death are cardiovascular disease and extra-hepatic 
142 cancers(29). A growing body of evidence suggests the effects of NAFLD extend beyond the liver, and 
143 NAFLD precedes and/or exacerbates the development of type 2 diabetes, hypertension and 
144 cardiovascular disease(33). From a public health perspective, NAFLD, in particular NASH, cannot be 
145 ignored. 
146 Pathogenesis
147 NAFLD is a complex phenotype that arises from dynamic interactions between diet, lifestyle and 
148 genetic factors, and involving crosstalk between multiple organs and the intestinal microbiome. 
149 Mechanistically, NAFLD pathogenesis can be viewed as an imbalance between lipid accumulation 
150 and removal (Fig. 2). Fatty acids arise in the liver from either the diet (dietary fats delivered via 
151 chylomicrons or dietary sugars converted via de novo lipogenesis; DNL), or from the circulating non-
152 esterified fatty acid (NEFA) pool. Under normal circumstances fatty acids (FA) are either oxidized 
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153 for energy or packaged into triacylglycerol (TAG) for export and circulation in very low-density 
154 lipoproteins (VLDL). 
155 The seminal view of NASH pathogenesis was one of two hits(34), where steatosis was 
156 followed by oxidative stress leading to lipid peroxidation and inflammation. Layers of complexity, 
157 and multiple hits are now recognized around these pathways; including genetic susceptibility, 
158 biological environment, behavioural factors, metabolism and the intestinal microbiome(35,36). In 
159 particular over the last decade, the roles of lipotoxic intermediates(37,38) and hepatic fatty acid 
160 trafficking(39) in NAFLD pathogenesis has come to be appreciated (Fig. 2). Intermediates in the 
161 synthesis of TAG (lysophosphatidic acid, phosphatidic acid, lysophosphatidyl choline, ceramides and 
162 diacylglycerols) are now recognized to contribute to altered insulin signalling(37). In addition, 
163 lipotoxic intermediates are released via extracellular vesicles also activating hepatic stellate cells 
164 (HSCs) and other parenchymal cells driving inflammation and fibrosis(38). 
165 The dynamics of lipid droplet formation(40), and the role of autophagy in fat mobilization(41) 
166 are also very active areas of research. Identification of the genetic risk variants described below, has 
167 underscored that lipid droplets are not merely inert bundles of triacylglycerol; they contain other lipid 
168 species, most notably cholesterol esters, and are associated with a diverse array of proteins. Notably, 
169 lipolysis of TAG from both adipocyte and hepatocyte lipid droplets is more dynamic and complex 
170 than previously envisioned, and lipid droplet associated proteins play a role in NAFLD 
171 pathogenesis(42). 
172 The progression of NAFLD involves an interplay of multiple cell types residing in the liver 
173 (Fig. 2). Lipotoxic intermediates, reactive oxygen species (ROS), endotoxins and adipokines, all drive 
174 recruitment and signalling of immune cells, including Kupffer cells (KC); along with the activation 
175 of HSCs (Fig. 2). Activated HSCs become fibroblasts, producing fibrogenic factors and collagen, and 
176 through apoptosis drive cirrhosis development(43). The chronic oxidative metabolism observed in 
177 NAFLD enhances ROS production creating a pro-oxidative state(44). This overall increase in pro-
178 oxidative/pro-inflammatory state leads to intracellular damage, activating repair mechanisms that can 
179 become hyperactive, further driving fibrosis(43). 
180 Genetic risk factors
181 Initially identified through genome-wide association scanning as contributing to individual and ethnic 
182 differences in hepatic fat content and susceptibility to NAFLD(45); a missense mutation, leading to an 
183 isoleucine to methionine substitution at position 148, in the patatin-like phospholipase domain 
184 containing 3 protein (PNPLA3; I148M variant, rs738409), has now been independently verified as 
185 associated with NAFLD severity in multiple populations. Individuals who are homozygous for this 
186 allele have markedly increased steatosis levels compared with non-carriers(45) and the minor allele 
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187 frequency correlates positively with steatosis across populations(14). This genetic variant is estimated 
188 to account for 30-50% of high-risk progression of NAFLD towards fibrosis, cirrhosis and HCC(46). 
189 In addition, it has also been linked to alcoholic(47) and viral(48) liver disease severity as well as HCC(49). 
190 This suggests the PNPLA3 variant is not specific to NAFLD, but more generally influences 
191 susceptibility to liver disease with environmental factors (viral or toxin exposure, nutrition/diet, 
192 microbiome) playing an integral, and perhaps deterministic role. Subsequent biochemical work has 
193 demonstrated that the PNPLA3 protein is associated with lipid droplets and has hydrolase (lipase) 
194 activity against TAG in hepatocytes and against retinyl esters in HSCs(50-52). Disruption of PNPLA3 
195 function leads to accumulation of TAG in hepatocytes; and the rs738409 risk allele is associated with 
196 severity of a variety of liver diseases(53). 
197 Three other common genetic variants also robustly associate with the development and 
198 progression of NAFLD and other liver diseases(36). Intriguingly, these genes all encode proteins 
199 involved in the regulation of hepatocyte lipid metabolism and are linked to the severity of multiple 
200 liver diseases. In particular the rs58542926 variant of the transmembrane 6 superfamily member 2 
201 protein (TM6SF2) results in a loss-of-function, inducing higher liver TAG content and lower 
202 circulating lipoproteins(54) through disrupted hepatocyte secretion of TAG and VLDL. Somewhat 
203 paradoxically, carriers of this mutation are at greater risk of liver disease but lower risk of 
204 cardiovascular events(55). In addition, a common polymorphism (rs641738, C>T) variant in the 
205 membrane bound O-acyltransferase domain-containing 7 (MBOAT7) gene has also been recently 
206 associated with alcoholic liver disease(56), NAFLD severity(57,58) and HCC(59). The variant reduces 
207 protein expression and alters phosphatidylinositol concentrations in the liver(57). Variation in the 
208 glucokinase regulator (GCKR) gene, which regulates de novo lipogenesis by controlling the influx 
209 of glucose in hepatocytes, has also been associated with NAFLD in multiple studies(60-62). The 
210 associated variant (rs780094) appears to be in linkage disequilibrium with a common missense loss-
211 of-function GCKR mutation (rs1260326) that effects it ability to negatively regulate glucokinase, 
212 resulting in an increase in hepatocyte glucose uptake and glycolytic flux, promoting lipogenesis and 
213 hepatic steatosis(63).
214 Possessing multiple risk alleles increases risk severity for NASH, fibrosis(64) and HCC(59). 
215 While it is hoped that in the near future polygenic risk scores may improve clinical stratification and 
216 management, there is undoubtedly genetic complexity yet to be elucidated. For example, only in 
217 March of 2018, Regeneron scientists reported their identification of splice variant rs72613567 (T>A) 
218 in the hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) gene and its association with reduced 
219 levels of alanine transaminase and protection against chronic liver disease(65). The association was 
220 identified by exome sequencing of 46,544 participants with corresponding electronic health records, 
221 and then replicated in four independent cohorts. The rs72613567 variant results in a truncated protein 
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222 with loss of enzymatic function that is associated with reduced risk of NASH and fibrosis, but not 
223 steatosis, suggesting the variant allele protects against progression to more clinically advanced stages 
224 of chronic liver disease. Interestingly, previous work had identified 17-beta-hydroxysteroid 
225 dehydrogenase 13 as overexpressed from hepatic lipid droplets from fatty liver patients and shown 
226 that adenovirus driven overexpression in mice induced a fatty liver phenotype(66). The physiological 
227 substrate(s) for the enzyme remain unknown, but in vitro it has activity against numerous steroid and 
228 bioactive lipids (e.g., leukotriene B4) (65). These data highlight again the role of lipid intermediates 
229 and lipid droplet dynamics in the pathogenesis of NAFLD, and open the possibility of targeting 
230 HSD17B13 therapeutically. 
231 Nutrition and non-alcoholic fatty liver disease 
232 While genetic mechanisms continue to be described, it is important to acknowledge the interplay 
233 between genetic background and environmental factors. Although, genetic risk for NAFLD 
234 influences pathogenesis, the phenotypic threshold is strongly influenced by environmental factors 
235 such as adiposity, insulin resistance and diet(36).  For example, recent work has demonstrated that for 
236 three of the aforementioned risk variants (PNPLA3, TM6SF2, GCKR), adiposity as measured by 
237 BMI greatly amplified the genetic risk(67). With NAFLD disease progression linked closely to obesity 
238 and type 2 diabetes, it is clear that diet and lifestyle are key modifiable risk factors.
239 Weight loss for the treatment of NAFLD
240 Hyper-energetic diets, containing high levels of saturated fat, refined carbohydrates and sugar 
241 sweetened beverages, are strongly implicated in NAFLD pathogenesis. Weight gain and obesity are 
242 closely associated with NAFLD progression, therefore dietary and lifestyle changes aimed at weight 
243 loss are fundamental to all clinical management guidelines for NAFLD(1,7,8). This includes eating a 
244 healthy diet and increasing physical activity to prevent and resolve NAFLD, regardless of BMI, as 
245 advised by both the UKs National Institute for Health and Care Excellence(8) and the European 
246 Association for the Study of the Liver (EASL)(7). Significant reduction in steatosis and hepatic 
247 markers of NAFLD have generally been observed with 5-10% weight loss (68,69); although weight 
248 reductions of >10% may be required for resolution of NASH and reducing fibrosis and portal 
249 inflammation(70). In general, combining dietary and physical activity interventions appears most 
250 effective, as are interventions of longer duration and greater intensity (multicomponent; more contact 
251 time, 14 times in 6 months); although trial heterogeneity can confound systematic review(68,69,71). 
252 Because achieving and maintaining 5-10% weight loss is a significant challenge for many(69,72), a 
253 pertinent question is whether or not improving the nutritional quality of the diet and/or increasing 
254 physical activity may improve NAFLD in the absence of weight loss(73).
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255 While the focus of this review is the role of nutrition and dietary modification, increasing 
256 physical activity is an important component of lifestyle change aimed at weight loss and clinical 
257 improvement of NAFLD. Randomized clinical trials assessing the effects of resistance training, 
258 aerobic exercise or a combination of both have reported improvements in liver enzyme levels and 
259 reduced intrahepatic TAG measured by magnetic resonance spectroscopy(68,74). Positive effects have 
260 been reported in patients engaging in physical activity only once a week(75), and meta-analysis shows 
261 this to be independent of significant weight change(74). Mechanistically this is plausible, as exercise 
262 has potent anti-inflammatory effects and protects against many chronic inflammatory diseases(76,77). 
263 Nonetheless, meta-analysis also suggests benefits are substantially greater with weight loss, 
264 particularly where weight loss exceeds 7%; with meta-regression demonstrating reductions in liver 
265 fat proportionally related to the magnitude of weight loss induced(74). 
266 Macronutrient composition and the Mediterranean diet 
267 The benefits of altering macronutrient composition and dietary patterns in NAFLD has been explored. 
268 In particular the Mediterranean diet is attractive given the body of evidence suggesting this dietary 
269 pattern reduces metabolic risk factors and cardiovascular disease risk(78-82). On this theoretical basis 
270 and only one randomised trial(83) in 12 NAFLD subjects at the time, the EASL Clinical Practice 
271 Guidelines made a strong recommendation that, in addition to aiming for a 7-10% weight reduction, 
272 macronutrient composition should be adjusted according to the Mediterranean diet(7). 
273 Primarily a plant-based diet characterized by high intakes of vegetables, legumes, fruits, nuts and 
274 whole grains, along with olive oil as the main source of added fat; the Mediterranean diet is typified 
275 by low intakes of dairy and meat products, higher intakes of fish and seafood, and moderate (red) 
276 wine consumption. In terms of macronutrients it tends to be much higher in fiber (>33g/d), lower in 
277 carbohydrates, higher in total and monounsaturated fat (~37% and ~18%), but lower in saturated fat 
278 (9%) than typical Western diets(81). As reviewed in detail by Zelber-Sagi(81) the evidence base for the 
279 Mediterranean diet and NAFLD remains limited and largely observational. Nonetheless, the data to 
280 date are consistently in favor of a beneficial effect from the Mediterranean diet for treating NAFLD, 
281 even without accompanying weight reduction. 
282 Recent work suggests that switching to either an isocaloric low-fat or Mediterranean diet for 
283 12 weeks, even ab libitum, can reduce liver fat (25% in low-fat and 32% in the Mediterranean diet; 
284 p=0.32) and alanine transaminase levels with minimal weight loss (1.6-2.1 kg). The Mediterranean 
285 diet did have better adherence and additional cardiometabolic benefits with improvements seen in 
286 total cholesterol, serum triglyceride, hemoglobin A1c (HbA1c) and the Framingham risk score(84). 
287 While the intervention was not designed for weight loss, and there was no difference in the caloric 
288 intakes measured at baseline and 12 weeks, both groups lost a small (2%) amount of weight, lower 
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289 than that typically associated with NAFLD improvement. Although no differences were observed in 
290 the reductions of liver fat and body weight between the dietary groups, improvements in total 
291 cholesterol, plasma triglycerides, and HbA1c levels were observed in the Mediterranean diet group. 
292
293 Saturated fat
294 What both low-fat (<35%) and the Mediterranean diet often have in common, is reduced 
295 (<10%) saturated fat relative to the Western diet. Although dietary sugars, in particular fructose 
296 discussed in the next section, have been scrutinised for their role in driving de novo lipogenesis and 
297 NAFLD pathogenesis(85,86), overfeeding saturated fat is more metabolically harmful to the liver(87). 
298 Specifically, using stable isotopes in combination with MRI, Luukkonen and colleagues showed that 
299 3 weeks of overfeeding (1000kcal/day) with saturated fat, simple sugars or unsaturated fats increased 
300 liver fat by 55%, 33% and 15% respectively. Furthermore, overfeeding saturated fat induced insulin 
301 resistance and endotoxemia, and increased multiple plasma ceramides(87). Recent focus on the 
302 negative metabolic effects of a high sugar diet has led to debate over historical dietary guidelines, 
303 which recommend low-fat and low saturated fat diets for the prevention of cardiovascular 
304 disease(88,89). It bears noting that low-fat is considered <35% of daily energy from fat with an 
305 acceptable distribution of 20-35% and low-saturated fat is considered 7-10% of total energy. In the 
306 US(90) and the UK(91) adults consume an average of 34-35% of daily energy intake from fat. As 
307 highlighted by Maldonado and colleagues(92), neglected in the often polarized debates around sugar 
308 or fat(93,94), is the fact that at a population level, identifying individual culpable nutrients is 
309 problematic. The vast majority of adults in developed countries consume excess energy from foods 
310 high in both sugar and fat, fundamentally contributing to increasing obesity and NAFLD. Where low-
311 fat versus low-carbohydrate has been examined in a NAFLD context, the results are similar to that 
312 seen in the meta-analysis of weight loss trials in diabetes(72); whereas low carbohydrate may induce 
313 a greater weight loss in short term (12 weeks), in long term the net weight loss tends to be similar to 
314 that from low-fat(68,71). 
315 Fructose and dietary sugars
316 Nonetheless, given the excessive consumption of sugar in general(86), messages of reducing sugar 
317 sweetened beverages and added sugars, consuming healthy (e.g. complex) carbohydrates alongside 
318 lowering saturated fat intake and consuming more healthy fats (e.g. monounsaturated and omega-3 
319 fatty acids) seem highly prudent. It is noted that beyond the obvious culprits of sugar sweetened 
320 beverages, biscuits and sweeties or candies, even foods with healthful components such as yogurts 
321 can have surprisingly high amounts of added sugars(95). 0Lowering intakes of fructose and high 
322 glycemic index foods in the diet have been shown to have beneficial effects in NAFLD patients(96,97). 
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323 Whereas the the EASL Clinical Practice Guidelines specifically suggest exclusion of NAFLD-
324 promoting components (processed food, and food and beverages high in added fructose)(7); the UK 
325 guidelines cited a lack of scientific studies meeting their inclusion and exclusion criteria, in not yet 
326 making specific recommendations(8). Fructose has been scrutinised because fructose consumption has 
327 risen in parallel with obesity, it is metabolized differently by liver and, at high experimental doses, 
328 exacerbates obesity and NAFLD(85). Furthermore, genetic predisposition may make some populations 
329 more susceptible to fructose consumption and liver disease than others(98). 
330 However, it remains challenging to separate out the effects of specific monosaccharides from 
331 the effects of excess energy. The experimental doses typically shown to be lipogenic (20% total 
332 energy) far exceed the population median amounts consumed and individuals rarely consume single 
333 sugars in isolation(86). When excess energy has been carefully controlled for in randomized controlled 
334 human feeding trials, no differential effects are seen between the lipogenic effects of fructose and 
335 glucose(99). A systematic review of controlled fructose feeding trials with NAFLD related endpoints 
336 examined 13 trials in total, including 7 isocaloric trials where fructose exchanged for other 
337 carbohydrates and 6 hypercaloric trials; diet supplemented with excess energy (2135% energy) from 
338 high-dose fructose (104220 g/day)(100). It concluded that in healthy participants isocaloric exchange 
339 of fructose for other carbohydrates does not induce NAFLD changes, however, extreme doses 
340 providing excess energy increase steatosis and liver enzymes; in agreement with computational 
341 modelling of hepatocyte lipogenesis in response to excess glucose and fructose, described in more 
342 detail below(92). 
343 There is worldwide agreement on the need to reduce the consumption of dietary sugars to 
344 prevent obesity and in particular reduce the consumption of sugar sweetened beverages to reduce the 
345 incidence of type 2 diabetes(86). Whereas strict restriction of free sugars (to <3% of total energy) for 
346 8 weeks has recently been shown to decrease hepatic steatosis in adolescents(101), it is not clear in the 
347 context of the prevention or treatment of NAFLD, whether public health messages focusing on 
348 fructose monosaccharides rather than free sugars and total energy is useful. An overall message 
349 should be that given the majority of populations worldwide are consuming too much total sugar, and 
350 given the dramatic increase in NAFLD and type 2 diabetes, reducing free sugar intake and choosing 
351 a more healthful diet in terms of macro- and micronutrients will be beneficial. Sugar sweetened 
352 beverages in particular, convey an additional risk for type 2 diabetes, most especially in young people, 
353 and should be restricted for the prevention of obesity and eliminated altogether in the treatment of 
354 existing NAFLD. 
355
356
Page 11 of 31
Cambridge University Press
Proceedings of the Nutrition Society
For Peer Review
12
357 Supplemental nutrients: omega-3 PUFAs, vitamin E & vitamin D
358 A variety of vitamins and micronutrients have been implicated in NAFLD pathogenesis. This is either 
359 because of epidemiological data associating a deficiency with disease or because of plausible anti-
360 steatotic, anti-inflammatory or anti-fibrotic mechanisms that (a supplemental dose of) dietary 
361 nutrients or other components may confer in a disease state. 
362 NAFLD patients have been shown to have lower intakes of fish(102) and omega-3 PUFAs(103) 
363 in comparison to controls and therefore PUFA supplementation has been explored. Two independent 
364 groups have systematically reviewed control intervention trials that examined omega-3 fatty acid 
365 supplementation for the treatment of NAFLD(104,105). Both meta-analyses included 18 independent 
366 trials with >1400 participants and concluded that supplementation of omega 3 PUFAs reduced 
367 steatosis as measured by ultrasound or MRI, and liver enzymes(104,105). Disappointingly, in the four 
368 trials that examined histological markers, omega-3 PUFA supplementation did not improve 
369 inflammation, ballooning or fibrosis(104). Strikingly, responders and non-responders to 
370 supplementation that correspond to improvements in liver markers were clearly evident in the well-
371 designed trial by Scorletti and colleagues(106). As discussed below, personalized nutrition for the 
372 prevention of chronic disease in the near future might account for inherent (genetic, epigenetic or 
373 microbiome mechanisms) inter-individual variation.
374 Vitamin E is a powerful antioxidant that helps protect cells against free radical damage, one 
375 of the pathogenic insults that drives NAFLD progression. There have now been several well-designed 
376 multi-centre trials in both adults and children examining vitamin E supplementation at 
377 pharmacological doses that could not be obtained through diet(107). Several meta-analyses show 
378 benefit from supplemental vitamin E on steatosis, inflammation, and ballooning in NASH, although 
379 the extent to which vitamin E benefits fibrosis remains unclear(108-110). Consequently, UK, EU and 
380 US clinical guidelines indicate vitamin E as a therapeutic option once a patient is in second or tertiary 
381 care for NASH(1,7,8), but with the awareness of potential risks for long-term vitamin E 
382 supplementation(107). Recommended doses are typically 800 IU/d as opposed to recommended 
383 nutrient intakes of Y$	O (22.4 IU/d) in the UK. While the American guidelines specify vitamin E 
384 only for NASH patients without diabetes(1), the UK guidelines consider vitamin E an option for 
385 patients with and without diabetes(8). 
386 A growing body of research suggests a relationship between vitamin D deficiency and chronic 
387 liver disease, in particular NAFLD, with low levels of serum 25-hydroxyvitamin D (25OHD) strongly 
388 associated with hepatic inflammation(111-113). Low levels of dietary vitamin D(114) and serum 25OHD 
389 are widespread, and vitamin D deficiency and insufficiency have been observed in pediatric 
390 NAFLD(115). In addition, polymorphisms within vitamin D metabolic pathway genes associate with 
391 the histological severity of pediatric NAFLD(115). However, the results of oral vitamin D 
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392 supplementation trials on adult NAFLD patients are conflicting(116,117). Some studies have 
393 demonstrated a correlation between NAFLD and NASH severity and lower levels of vitamin D(118). 
394 However, others, including a meta-analysis with 974 adult patients find no such relationships(119,120). 
395 The determinants of 25OHD bioavailability are complex; genetic variation determines serum 
396 levels of vitamin D binding protein thus influencing bound and free 25OHD(121). Inter-individual 
397 vitamin D concentrations are highly variable and the degree to which they change over the decades 
398 through which NAFLD may progress, is unknown. The mechanisms behind the role of vitamin D in 
399 NAFLD pathogenesis are not yet fully understood and there are likely to be both hepatic and extra-
400 hepatic mechanisms involved. Interestingly, vitamin D has been shown to have antifibrotic effects of 
401 vitamin D in both rodent(122,123) and human(124) HSCs. While there are clearly likely to be multiple 
402 pathways to fibrogenesis in NAFLD(125), together these studies show a role for vitamin D in liver 
403 disease pathogenesis and suggest common polymorphisms influencing vitamin D homeostasis may 
404 be relevant to NAFLD. Although supplementation with vitamin D has not been demonstrated an 
405 effective intervention in the limited studies done in adult patients with NAFLD to date; further 
406 research is warranted into whether targeted supplementation, either in genetically susceptible or 
407 pediatric populations may be indicated.
408 While, data from large well controlled trials are limited, it may be that classical intervention 
409 trials for single nutrients are doomed to fail in light of the high inter-individual genetic variation in 
410 the metabolism of many of these nutrients; in combination with individual epigenetic, microbiome 
411 and environmental, namely dietary, effects. As illustrated for omega-3 supplementation(106), 
412 population studies will include non-responders that may mask the positive (or negative) effects of 
413 dietary supplements in others. As will be discussed, the goal of personalised nutrition is to stratify 
414 dietary intervention according to such genetic, omic and clinical information in the first instance to 
415 maximise therapeutic benefit. 
416 Systems biology
417 Systems biology is the application of mathematical or computational modelling to biological systems, 
418 and has evolved as a complementary method of understanding a biological organism. Reflecting its 
419 roots in mathematical graph theory, cybernetics and general systems theory; within systems biology, 
420 biological systems, whether a signalling network, a cell, an organ, or an organism, are visualized and 
421 modelled as integrated and interacting networks of elements from which coherent function 
422 emerges(126). As illustrated in Fig. 3A, from a systems point of view, a human may be deconstructed 
423 into a series of networks at organ, cellular and the molecular or genetic levels; equally, humans are 
424 parts within larger social networks. Underpinning systems biology are advanced mathematical theory 
425 and computational approaches that aim to model organism function and predict behaviour. Early in 
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426 its evolution, computational systems biology was envisioned as working best if integrated in an 
427 iterative cycle of model development and prediction, with experimental (wet lab) investigation and 
428 model refinement (Fig. 3B)(127). This iterative cycle moves from hypothesis-led experiments 
429 generating data that can both yield biological insights, and can be further utilized in the reconstruction 
430 of mathematical network models (such as the extended Petri net model of insulin signalling illustrated 
431 in Fig. 3C) for predictive simulation, model refinement and more biological insight that informs 
432 further experimental hypotheses. 
433 Systems medicine and personalized nutrition
434 Systems pharmacology and systems medicine are subtypes of systems biology underpinning current 
435 efforts in what has been alternately termed stratified, personalized or precision medicine(128). 
436 Emerging out of the genomics revolution, came the recognition that whereas currently used 
437 pharmaceuticals are based on clinical trials involving large cohorts, these neglect the underlying 
438 genetic and environmental heterogeneity represented within the population. This heterogeneity 
439 explains the existence of responders and non-responders to drug intervention, as well as drug off-
440 target effects. Precision medicine aims for the stratification of patients into tightly molecularly 
441 defined groups (based on multiple types of omics data), with effective interventions or treatments 
442 defined for each(129). While currently used stratified medicines are largely within the cancer field and 
443 rely on genetic testing of a relatively limited number of genes, ultimately it is envisioned that the 
444 integrative analyses of different types of data: clinical, genomic, proteomic, metabolomic; will yield 
445 system insights (Fig. 3D). Beyond the genomic vision of stratified medicine, systems medicine in its 
446 grandest vision, has been described as personalized, predictive, preventive and participatory medicine 
447 (4P medicine) and intriguingly perhaps for Nutritional Scientists, has an aim of quantifying wellness 
448 in addition to understanding disease(130,131).
449 Arguably, the Nutritional Sciences are ideal for the use of systems approaches given the 
450 complex, dynamic nature of diet where small effects may be magnified on a chronic time scale; and 
451 furthermore, occur against a backdrop of tremendous genetic diversity both of humans and their 
452 intestinal microbiomes(132). The vision and aim of personalised nutrition mimics that of personalised 
453 medicine, e.g. tailoring diets in a way that optimises health outcomes for the individual based on their 
454 omics data(133). Currently it is estimated only 40% of a cohort may respond to a dietary intervention; 
455 analogous to observed nonresponse or off-target effects to pharmaceutical compounds. This is 
456 attributed to inter-individual variation in a host of variables (sex, habitual dietary habits, genetics, 
457 epigenetics, and gut microbiota) effecting individual absorption, distribution, metabolism, and 
458 excretion of compounds and metabolites(134). Personalised nutrition therefore, presents both grand 
459 opportunities and challenges; e.g. how to capture small, accumulative factors that only manifest into 
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460 disease over a matter of years, while distinguishing differential effects of one nutritional component 
461 from hundreds of others(135). 
462 Modelling liver metabolism
463 In more recent years, systems biology approaches have been applied to human metabolism at the 
464 genome scale. Genome-scale metabolic networks (GMSNs) may be thought of as essentially an 
465 organized list of metabolic reactions derived from all available data of an organisms metabolism into 
466 a mathematically structured network. Constraint-based flux balance analysis is used to predict 
467 metabolic fluxes in silico, while the GSMN is constrained mathematically based on experimental data 
468 sets. The liver as an organ is central to both human metabolism and overall homeostasis; and the first 
469 liver-specific genome-scale metabolic networks (GMSNs) were published in 2010(136,137). While one 
470 of these was derived from a generic GSMN by automated methods integrating tissue-specific 
471 datasets(136); the model presented by Gille and colleagues(137) was based on exhaustive manual 
472 curation of transcript, protein, biochemical and physiological data and contains 2539 reactions and 
473 777 individual metabolites.  
474 More recently, the liver-specific iHepatocytes2322(138) was reconstructed, comprising 7,930 
475 reactions, 2,895 unique metabolites in 8 different compartments mapped to 2,322 genes. This was 
476 done in semi-automated fashion but, significantly, utilized proteomics expression data from 
477 hepatocytes from the Human Protein Atlas(139) to establish tissue specificity. This incredibly 
478 comprehensive reconstruction paid particular attention to manual curation of reactions involving 
479 lipids. Both of these GSMNs have been utilized in the context of NAFLD related research. While 
480 GSMNs continue to evolve as powerful tools, it is important to note that metabolism is only one of 
481 the many networks considered in systems biology (Fig. 3A) and flux balance analysis is limited in 
482 being static and not reflecting the dynamic metabolic response to altered cell signaling. A very active 
483 area of systems research is focused on developing novel tools and algorithms for integrating and 
484 simulating models at multiple scales and linking GSMNs to gene regulatory networks and/or PBPK 
485 models in systems pharmacology/toxicology and kinetic signaling networks(140-142).
486 Application of systems approaches to NAFLD
487 It has only been in very recent years that GSMNs have been used along with relevant omics data in 
488 the context of NAFLD. The aforementioned iHepatocytes2322(138) was reconstructed specifically to 
489 interrogate liver transcriptomic data from 19 healthy subjects and 26 patients with varying degrees of 
490 NAFLD. Using a metabolite reporting algorithm, a pair-wise comparison was used to identify 
491 reporter metabolites. Network subgroup analyses predicted disruptions in the non-essential amino 
492 acids: serine, glutamate and glycine (along with others), along with metabolites in the folate pathway 
493 related to the interconversion of serine, glycine and glutamate. Phosphatidylserine, an essential 
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494 component of lipid droplets was also identified as disrupted, with the mRNA for enzymes involved 
495 in its synthesis found downregulated in the NASH patients. Similarly, several enzymes that either use 
496 serine as substrate or produce it as a product were transcriptionally downregulated. Collectively, the 
497 authors inferred an endogenous serine deficiency and suggested serine supplementation as a possible 
498 intervention in NASH. Chondroitin and heparin sulphate levels were also identified as potential 
499 NAFLD biomarkers, although these have not yet been independently validated. 
500 Impressive follow up work from the same group has now shown in an untargeted 
501 metabolomics analysis of individuals with either low (mean 2.8%, n=43) or high (mean 13.4%, n=43) 
502 liver fat as measured by MRI, decreased levels of glycine and serine, along with betaine and N-
503 acetylglycine associated with higher levels of steatosis(143). In addition to the metabolomic 
504 measurements, in vivo VLDL kinetics were measured via stable isotope infusion in 73 of the 
505 individuals. These experimentally measured VLDL secretion rates along with individually defined 
506 NEFA uptake rates (based on body composition and secretion rates of NEFA from adipose and 
507 muscle) were used to constrain the iHepatocytes2322 GSMN. The resulting personalized GSMNs 
508 were then simulated using the secretion rate of VLDL as an objective function in order to identify 
509 hepatic metabolic alterations between individuals with high and low steatosis. Liver fluxes were 
510 predicted for each subject and several reactions, consistent with an increased demand for 
511 nicotinamide adenine dinucleotide (NAD+) and glutathione, correlated to steatosis and net fat influx. 
512 Relating this back to amino acid precursors and the lower levels of serum serine and glycine, 
513 in a proof-of-concept study in six subjects with obesity, Mardinoglu and colleagues observed both a 
514 decrease in liver fat (mean 26.8 to 20.4%) and aspartate and alanine transaminase levels after 14 days 
515 of serine supplementation (~20 g of L-serine, 200 mg/kg/day)(143).  The authors suggest serine could 
516 be combined with N-acetylcysteine, nicotinamide riboside and L-carnitine as a supplement to aid in 
517 mitochondrial fatty acid uptake and oxidation and increased generation of glutathione may have 
518 benefit for either the prevention or treatment of NASH. While pilot trials have examined N-
519 acetylcysteine(144,145) and L-carnitine(146,147) supplementation in NAFLD separately with mixed 
520 results, they have not been examined in combination. Amino acid disturbances, particularly to 
521 glutamate, serine and glycine continue to be explored in relation to NAFLD liver disease severity in 
522 different populations(148,149). Returning to the ideas of systems medicine and personalized nutrition, 
523 and the example of responders and non-responders to omega-3 supplementation, an open question is 
524 whether or not a subgroup of NAFLD patients are likely to benefit (respond) to such an intervention 
525 more than others. It is hoped with advances in systems biology the identification of such patient 
526 subgroups will be feasible in the near future.
527 Other work has also integrated transcriptomic data with experimentally measured in vivo flux 
528 measurements from NAFLD patients(150) utilising GSMNs. Hyötyläinen and workers used Recon1 
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529 and measured flux ratios of metabolites and bile acids across the hepatic venous splanchnic bed in 
530 nine subjects with NAFLD that were fasted and then underwent euglycemic hyperinsulinemia. The 
531 work developed a metabolic adaptability score and found steatosis is associated with overall reduced 
532 adaptability. Steatosis induced mitochondrial metabolism, lipolysis and glyceroneogenesis; plus, a 
533 switch from lactate to glycerol as a substrate for gluconeogenesis. In this, and the work of Mardinoglu 
534 and colleagues, GSMNs were utilized for the mechanistic interpretation of clinical (transcriptomic 
535 and metabolomic) NAFLD data. However, these models are static, reflecting liver adaptation at an 
536 endpoint, and do not give insight into the dynamic reprogramming of global metabolism and 
537 metabolic adaptation to maintain homoeostasis in response to stimulation as recently addressed by 
538 Maldonado and colleagues(92). 
539 Building on their previous work establishing the use of quasi-steady state Petri nets (QSSPN) 
540 to integrate and simulate gene regulatory networks and/or PBPK models with constraint-based 
541 GSMNs(140-142); the group have developed novel multi-scale models to predict the hepatocytes 
542 response to fat and sugar(92). In one case, from experimental -omics data and the literature, they 
543 manually curate a comprehensive network reconstruction of the peroxisome proliferator activated 
544 receptor alpha (PPARB) regulome. Integrated to the HepatoNet1(137) GSMN, the resulting multi-scale 
545 model reproduced metabolic responses to increased fatty acid levels and mimicked lipid loading in 
546 vitro. Adding to the conflicting literature on the role of PPARB in NAFLD, the model predicted that 
547 activation of ?B by lipids produces a bi-phasic response, which initially exacerbates steatosis(92). 
548 The data highlight potential challenges for the use of ?B agonists to treat NAFLD and illustrate 
549 how dynamic simulation and systems approaches can yield mechanistic explanations for drug off-
550 target effects. While the PPARB regulome module was sufficiently large to preclude complete 
551 deterministic parameters for every reaction; illustrating the flexibility of QSSPN, the authors also 
552 simulate a kinetic multi-scale model of monosaccharide transport and insulin signalling integrated to 
553 the HepatoNet1 GSMN. Interestingly, while the model predicted differential kinetics for the 
554 utilisation of glucose and fructose, TAG production was predicted to be similar from both 
555 monosaccharides. This finding is supported both by the authors experimental data presented 
556 alongside the simulations(92), as well as other clinical and intervention data(99,100).  These data imply 
557 that it is the quantity, not type of sugar that drives fat accumulation in liver cells and NAFLD per se. 
558 The focus here has been on reviewing recent work applying the simulation of GSMNs in 
559 NAFLD-related research. Computational approaches and network reconstructions are rapidly 
560 evolving and current models have strengths and weaknesses that will resolve in future iterations. 
561 More work is needed comparing results from different reconstructions and establishing best choice 
562 of objective functions for human applications. Integrating constraint-based analyses of GSMNs with 
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563 whole body PBPK models or gene regulatory and signalling network models in multi-scale fashion 
564 for dynamic simulations and insights into pathogenesis over time is a current research goal. 
565 Conclusions
566 The interdisciplinary methods of systems biology are rapidly evolving and have recently been applied 
567 to the study of NAFLD. Technology is rapidly evolving and a not too distance future is envisioned 
568 where individual genetic, proteomic and metabolomic information can be integrated computationally 
569 with clinical data. Ideally this will inform personalized nutrition and precision medicine approaches 
570 for improving prognosis to chronic diseases such as NAFLD, obesity and type 2 diabetes. Several 
571 genetic variants mediating susceptibility to liver diseases have been identified and validated, opening 
572 up possibilities for the use of polygenic risk scores to stratify patients once disease is identified. 
573 Progression of NAFLD is dependent on environmental factors and it should be stressed that NAFLD 
574 is reversible through lifestyle change. As has recently been argued for type 2 diabetes, a systems 
575 disease requires a systems solution(151). While intervention studies demonstrate that high-intensity 
576 combination interventions, including behaviour change alongside dietary and lifestyle change, are 
577 most efficacious for treating NAFLD; undoubtedly, broader societal systems level changes are 
578 urgently required to reduce the current burden and prevent obesity and related morbidities such as 
579 NAFLD and type 2 diabetes going forward. 
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599 Fig. 1 The dynamic spectrum of non-alcoholic fatty liver disease (NAFLD). The liver can accumulate 
600 fat (non-alcoholic fatty liver; NAFL) in the absence or presence of inflammation (non-alcoholic 
601 steatohepatitis; NASH) and fibrosis. These processes are reversible as indicated by the dashed arrows. 
602 Poor and over-nutrition can influence the development and progression of NAFLD as indicated by 
603 the red arrows; whereas weight loss and a healthy diet is the mainstay of successful NAFLD treatment 
604 as indicated by the green arrows. Evidence from clinical trials in NAFLD suggest even fibrosis can 
605 regress. Questions remain about whether the development of steatohepatitis is an independent 
606 maladaptive process from the development of steatosis; and whether hepatocellular carcinoma (HCC) 
607 can develop directly from NAFL and NASH without the development of fibrosis.
608 Fig. 2 Diet and non-alcoholic fatty liver disease pathogenesis. Fatty acids (FAs) arise in the liver from 
609 [1] de novo lipogenesis (DNL) of dietary sugars, [2] dietary fat via chylomicrons and [3] the non-
610 esterified fatty acid (NEFA) pool derived primarily from adipose tissue. In the context of normal 
611 physiology, FAs are either [4] oxidized for energy or [5] esterified into triacylglycerol (TAG) and 
612 exported in very low-density lipoprotein (VLDL) particles into circulation. In the context of excess 
613 energy, [6] TAG is stored in lipid droplets. Lipid intermediates, reactive oxygen species (ROS), 
614 endotoxins and adipokines all contribute to [7] inflammation, hepatic stellate cell (HSC) and Kupffer 
615 cell (KC) activation leading to liver fibrosis. Pathogenesis is influenced by genetic and epigenetic 
616 mechanisms and is influenced by the microbiome.
617 Fig. 3 Systems biology and systems medicine. A Humans may be deconstructed into a series of 
618 networks at genetic, molecular, cellular and organ levels; equally, humans are places within larger 
619 social networks. B Systems biology ideally is an iterative cycle from hypothesis-led experiments 
620 generating data that can both yield biological insights, and can be further utilized in the reconstruction 
621 of mathematical models for predictive simulation, model refinement and more biological insight that 
622 informs further experimental hypotheses. C A kinetic network model of insulin signalling 
623 reconstructed in a Petri net formalism, reprinted with permission(92). Coloured ovals used to highlight 
624 modules used by Kubota and colleagues(152). D Systems medicine and systems pharmacology 
625 integrate genetic, clinical and omic data into network models, representing an in silico human, that 
626 can yield emergent insights. For example, simulations may predict responders/non-responders to a 
627 drug or identify mechanisms of action underpinning drug off target effects.
628
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Fig. 1 The dynamic spectrum of non-alcoholic fatty liver disease (NAFLD). The liver can accumulate fat (non-
alcoholic fatty liver; NAFL) in the absence or presence of inflammation (non-alcoholic steatohepatitis; NASH) 
and fibrosis. These processes are reversible as indicated by the dashed arrows. Poor and over-nutrition can 
influence the development and progression of NAFLD as indicated by the red arrows; whereas weight loss 
and a healthy diet is the mainstay of successful NAFLD treatment as indicated by the green arrows. Evidence 
from clinical trials in NAFLD suggest even fibrosis can regress. Questions remain about whether the 
development of steatohepatitis is an independent maladaptive process from the development of steatosis; 
and whether hepatocellular carcinoma (HCC) can develop directly from NAFL and NASH without the 
development of fibrosis. 
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Fig. 2 Diet and non-alcoholic fatty liver disease pathogenesis. Fatty acids (FAs) arise in the liver from [1] de 
novo lipogenesis (DNL) of dietary sugars, [2] dietary fat via chylomicrons and [3] the non-esterified fatty 
acid (NEFA) pool derived primarily from adipose tissue. In the context of normal physiology, FAs are either 
[4] oxidized for energy or [5] esterified into triacylglycerol (TAG) and exported in very low-density 
lipoprotein (VLDL) particles into circulation. In the context of excess energy, [6] TAG is stored in lipid 
droplets. Lipid intermediates, reactive oxygen species (ROS), endotoxins and adipokines all contribute to [7] 
inflammation, hepatic stellate cell (HSC) and Kupffer cell (KC) activation leading to liver fibrosis. 
Pathogenesis is influenced by genetic and epigenetic mechanisms and is influenced by the microbiome. 
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Fig. 3 Systems biology and systems medicine. A Humans may be deconstructed into a series of networks at 
genetic, molecular, cellular and organ levels; equally, humans are places within larger social networks. B 
Systems biology ideally is an iterative cycle from hypothesis-led experiments generating data that can both 
yield biological insights, and can be further utilized in the reconstruction of mathematical models for 
predictive simulation, model refinement and more biological insight that informs further experimental 
hypotheses. C A kinetic network model of insulin signalling reconstructed in a Petri net formalism, reprinted 
with permission(92). Coloured ovals used to highlight modules used by Kubota and colleagues(152). D 
Systems medicine and systems pharmacology integrate genetic, clinical and omic data into network 
models, representing an in silico human, that can yield emergent insights. For example, simulations may 
predict responders/non-responders to a drug or identify mechanisms of action underpinning drug off target 
effects. 
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